RHS Financial LLC Takes Position in Gilead Sciences, Inc. $GILD

RHS Financial LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, Holdings Channel reports. The firm acquired 3,574 shares of the biopharmaceutical company’s stock, valued at approximately $452,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of GILD. Strategic Investment Solutions Inc. IL purchased a new stake in Gilead Sciences during the 4th quarter valued at $25,000. Persistent Asset Partners Ltd bought a new stake in Gilead Sciences in the second quarter worth $25,000. Vermillion & White Wealth Management Group LLC boosted its stake in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 85 shares during the period. Quattro Advisors LLC purchased a new position in Gilead Sciences during the fourth quarter worth $26,000. Finally, Wealth Preservation Advisors LLC increased its position in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on GILD. Barclays reduced their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 29th. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $133.00 to $155.00 in a research note on Monday, July 6th. Leerink Partners cut Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their target price for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. Finally, Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a report on Wednesday, May 20th. Twenty-four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $158.04.

Gilead Sciences Trading Up 3.3%

NASDAQ GILD opened at $143.44 on Wednesday. The company’s 50-day moving average price is $130.69 and its 200-day moving average price is $136.46. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The stock has a market cap of $177.86 billion, a PE ratio of -53.72 and a beta of 0.32. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter last year, the firm posted $2.01 EPS. The firm’s revenue was up 10.6% compared to the same quarter last year. Equities research analysts forecast that Gilead Sciences, Inc. will post -0.53 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $137.64, for a total value of $3,853,920.00. Following the transaction, the insider owned 118,234 shares of the company’s stock, valued at $16,273,727.76. This represents a 19.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $138.36, for a total value of $415,080.00. Following the transaction, the chief financial officer owned 165,646 shares in the company, valued at $22,918,780.56. The trade was a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 82,000 shares of company stock valued at $10,837,860. 0.30% of the stock is currently owned by company insiders.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: A federal appeals court blocked companies from importing and selling cheaper foreign versions of Biktarvy in the United States. The ruling helps protect revenue from Gilead’s leading HIV treatment and removes a potential competitive and pricing threat. Gilead stock court ruling on Biktarvy imports
• Positive Sentiment: Gilead’s HIV franchise remains the primary growth engine. Biktarvy continues to lead treatment, while the newer Yeztugo product and additional pipeline programs could expand the company’s prevention and treatment opportunities. Is Gilead’s Expanding HIV Portfolio a Growth Catalyst?
• Positive Sentiment: Commentary from The Motley Fool highlighted Gilead as an underappreciated healthcare turnaround story, citing double-digit quarterly revenue growth, strong HIV sales, acquisitions, and an expanding oncology portfolio. This supports investor optimism about longer-term diversification beyond HIV. Gilead Sciences turnaround story
• Neutral Sentiment: Gilead is participating in a highly competitive antibody-drug conjugate oncology market. The company’s technology and patent position may create future opportunities, but the landscape also involves substantial competition and development risk. Cancer and antibody-drug conjugates patent landscape
• Negative Sentiment: Chief Commercial Officer Johanna Mercier sold 28,000 shares worth approximately $3.85 million. Because the transaction occurred under a pre-arranged Rule 10b5-1 plan, it is a limited signal about management’s outlook, though insider selling can still weigh modestly on sentiment.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.